Technical Analysis for HMDCF - Hutchison China Ltd

Grade Last Price % Change Price Change
D 3.5000 -74.49% -10.2200
HMDCF closed down 74.49 percent on Wednesday, January 25, 2023, on 9 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Down

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Gapped Down Weakness 0.00%
New 52 Week Closing High Bullish -74.49%
New Uptrend Bullish -74.49%
Wide Range Bar Range Expansion -74.49%
Doji - Bearish? Reversal -74.49%
New 52 Week High Strength -74.49%
Multiple of Ten Bullish Other -74.49%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Hutchison China Ltd Description

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Cancer Clinical Medicine Chemical Compounds Breast Cancer Solid Tumors Colorectal Cancer Immunotherapies Lung Cancer Non Small Cell Lung Cancer Small Cell Lung Cancer Hepatocellular Carcinoma Non Small Cell Lung Carcinoma Targeted Therapy Gastric Cancer Hematological Malignancies Protein Kinase Inhibitor Sarcoma Bemcentinib Follicular Lymphoma Hematological Cancers Ros1 Tyrosine Kinase

Is HMDCF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.72
52 Week Low 1.61
Average Volume 1,243
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 3.0705
10-Day Moving Average 4.0420
Average True Range 1.5926
RSI 50.25
ADX 31.65
+DI 50.1307
-DI 4.9658
Chandelier Exit (Long, 3 ATRs) 8.9422
Chandelier Exit (Short, 3 ATRs) 6.3878
Upper Bollinger Bands 8.0792
Lower Bollinger Band -1.9382
Percent B (%b) 0.54
BandWidth 326.2465
MACD Line 1.0415
MACD Signal Line 0.5748
MACD Histogram 0.4667
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.5000
Resistance 3 (R3) 3.5000 3.5000 3.5000
Resistance 2 (R2) 3.5000 3.5000 3.5000 3.5000
Resistance 1 (R1) 3.5000 3.5000 3.5000 3.5000 3.5000
Pivot Point 3.5000 3.5000 3.5000 3.5000 3.5000
Support 1 (S1) 3.5000 3.5000 3.5000 3.5000 3.5000
Support 2 (S2) 3.5000 3.5000 3.5000 3.5000
Support 3 (S3) 3.5000 3.5000 3.5000
Support 4 (S4) 3.5000